Table II.
Characteristics of patients with CNS relapse (n=10).
| Clinical factor | CHOP-like (n=5) | R-CHOP-like (n=5) |
|---|---|---|
| Gender | ||
| Male | 2 | 4 |
| Female | 3 | 1 |
| Age (years), median (range) | 55 (40–59) | 43 (43–51) |
| B symptom | ||
| Yes | 2 | 1 |
| No | 3 | 4 |
| Stage | ||
| I–II | 2 | 4 |
| III–IV | 3 | 1 |
| ECOG | ||
| 0–1 | 5 | 4 |
| 2–4 | 0 | 1 |
| LDH | ||
| Normal | 2 | 5 |
| Elevated | 3 | 0 |
| Extranodal sites | ||
| <2 | 3 | 4 |
| ≥2 | 2 | 1 |
| IPI | ||
| 0–2 | 3 | 4 |
| 3–5 | 2 | 1 |
| aaIPI | ||
| 0–1 | 3 | 4 |
| 2–3 | 2 | 1 |
| Bone marrow | ||
| No | 5 | 5 |
| Yes | 0 | 0 |
| Primary site | ||
| Lymph node | 1 | 1 |
| Testis | 0 | 3 |
| Bone | 0 | 1 |
| Ileocecal junction | 1 | 0 |
| Lung | 1 | 0 |
| Adrenal gland | 1 | 0 |
| Breast | 1 | 0 |
| Site of CNS relapse | ||
| Parenchymal | 4 | 5 |
| Leptomeninges | 1 | 0 |
| Response to initial treatment | ||
| Complete response | 3 | 5 |
| Partial response | 0 | 0 |
| No response or progressive disease | 2 | 0 |
| Relapse in CNS versus systemic | ||
| First relapse in CNS only | 4 | 4 |
| First relapse in CNS simultaneously with other sites | 0 | 0 |
| First relapse in other sites then CNS | 1 | 0 |
| First relapse in CNS then other sites | 0 | 1 |
CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP, rituximab with CHOP; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; aaIPI, age-adjusted IPI; CNS, central nervous system.